5 Best Dividend Stocks to Buy According to D. E. Shaw

2. Eli Lilly and Company (NYSE:LLY)

D E Shaw’s Stake Value: $586,244,842

On June 9, Jefferies raised its price recommendation on Eli Lilly and Company (NYSE:LLY) to $1,350 from $1,330. It reiterated a Buy rating on the shares. The move followed the release of full data from retatrutide’s TRIUMPH-1 obesity study and the TRANSCEND-T2D-1 study in patients with Type 2 diabetes mellitus. While the firm noted some safety observations, it believes these issues are manageable. Jefferies also argued that retatrutide’s overall profile “will be difficult to beat” in a modern large-scale global obesity Phase 3 trial.

On June 8, Reuters reported that Eli Lilly shares gained 4% on Monday after the company released new data on its next-generation obesity drug, retatrutide. Analysts and investors expect the treatment to help strengthen Lilly’s position in the growing weight-loss market.

Lilly presented full results from two retatrutide studies at the American Diabetes Association meeting in New Orleans. One study involved treatment-naive Type 2 diabetes patients, while the other focused on patients with obesity. Investors were particularly encouraged by the performance of the lower 4 mg dose of retatrutide. The treatment delivered roughly 19% weight loss, a result comparable to the highest dose of Lilly’s blockbuster obesity drug, Zepbound.

Tolerability was broadly consistent with expectations, including similar rates of treatment discontinuation and relatively low levels of vomiting. Side effects increased at higher doses.

Eli Lilly and Company (NYSE:LLY) is a medicine company that discovers, develops, manufactures, and markets products through a single business segment focused on human pharmaceutical products.